TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/17/2021
Back to search
Official data from USPTO
KNACK
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
11/17/2021
Trademark type
Word
Nice classes
5
Filing date
03/01/2018
Registration date
10/26/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/26/2021
Last transaction
10/26/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/01/2021
First use in commerce
08/01/2021
Drawing code
4
Owner type
03
Owner location
New York City, NY
Examiner
MAYES, LAURIE
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
KNACK PHARMACEUTICALS, INC.
Representatives
Tomas Maria Casalins Fox Horan & Camerini LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of epilepsy disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of skin diseasesallergies and rheumatic disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of Alzheimer; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for for the treatment and prevention of metabolicendocrine and kidney related diseases and disorders; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for the treatment of bone disorders and bone diseases; Pharmaceutical preparations for the treatment of toxic effects; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for the prevention and treatment of hormone disorders and deficiencies; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for for the prevention and treatment of nausea and vomiting; Pharmaceutical preparations for the prevention and treatment of aids-related disorders and diseases; Pharmaceutical preparations for treatment and prevention of viral and bacterial infections; Pharmaceutical preparationsinjectable contraceptives
Publications
History of USPTO decisions and trademark events.
39 publications found
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
11/17/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/17/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/17/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
10/26/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/18/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/17/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/16/2021
IUAF
USE AMENDMENT FILED
09/10/2021
EISU
TEAS STATEMENT OF USE RECEIVED
09/10/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/17/2021
EX5G
SOU EXTENSION 5 GRANTED
03/16/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/16/2021
EXT5
SOU EXTENSION 5 FILED
03/02/2021
EEXT
SOU TEAS EXTENSION RECEIVED
03/02/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/08/2020
EX4G
SOU EXTENSION 4 GRANTED
08/06/2020
EXT4
SOU EXTENSION 4 FILED
08/06/2020
EEXT
SOU TEAS EXTENSION RECEIVED
08/06/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/07/2020
EX3G
SOU EXTENSION 3 GRANTED
03/05/2020
EXT3
SOU EXTENSION 3 FILED
03/05/2020
EEXT
SOU TEAS EXTENSION RECEIVED
03/05/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/30/2019
EX2G
SOU EXTENSION 2 GRANTED
08/28/2019
EXT2
SOU EXTENSION 2 FILED
08/28/2019
EEXT
SOU TEAS EXTENSION RECEIVED
08/28/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/05/2019
EX1G
SOU EXTENSION 1 GRANTED
03/01/2019
EXT1
SOU EXTENSION 1 FILED
03/01/2019
EEXT
SOU TEAS EXTENSION RECEIVED
03/01/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/11/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/17/2018
PUBO
PUBLISHED FOR OPPOSITION
07/17/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/27/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/13/2018
DOCK
ASSIGNED TO EXAMINER
06/13/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/08/2018
NWAP
NEW APPLICATION ENTERED
03/05/2018
Continuous trademark protection
Get notified about every new filing that threatens KNACK or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.